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Abstract
Since FV-Leiden polymorphism was first described in
1994, a growing number of polymorphic loci have been
identified in association with increased genetic risk for
thrombophilia. Often however, these risk factors have
been studied in isolation of the remaining known phe-
notype linked polymorphisms. This fact has, at least in
part, been justified by the laborious techniques tradi-
tionally used in the genotyping studies, as well as its
relatively high costs. Another major problem concern-
ing these studies has been the non-negligible incidence
of dubious genotypes, resulting from the manual,
labour intensive techniques applied, and their some-
times difficult to read output’s. These difficulties have
also hampered the widespread use of genotyping data
in the clinical assessment of the genetic risk levels both
in patients and their relatives, leaving some clinicians
less than convinced about its clinical usefulness. 
Recently however, the introduction of new genetic tech-
niques in the clinical genetics laboratory has started to
change this picture. Most notably, the advent of Real-
time-PCR has brought the possibility of genotyping
patients and controls at a large scale, with increased
specificity, automation and speed. Moreover, the use of
these techniques in the clinical genetics setting has not
only increased the quality of the results, but most
importantly has also increased our capability of answer-
ing questions at a deeper level. Among the new ques-
tions that can now be answered without increased costs
and uncertainty is the study of the association of genet-
ic risk factors in thrombophilia. Our results show that
indeed even common polymorphic loci may increase
our ability to further discriminate the genetic thrombo-
sis risk of individual patients and relatives.
It must however be noted that the innovation level in
the clinical genetics lab is just starting to grow. In fact
we haven’t even started to experience the advantages
brought about by the genome program, and its massive
identification of SNP’s. The technology to test these is
also presently being refined, and is expected to go from
research to the clinical lab in the near future. Only then,
can we expect to define with high certainty the com-
bined genetic risks for such complex pathologies as the
thrombophilias.
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Materials and methods
A total of 863 individuals (226 healthy blood donors, 253
arterial thrombosis patients and 384 venous thrombosis
patients were included in the study. Arterial thrombosis events
included 16 patients with ischemic thrombosis, 157 with
stroke, 59 with myocardial infarction, 9 with retinal artery
thrombosis, 6 with pulmonary artery thrombosis and 6 with
other arterial thrombosis. Venous thrombosis events included
13 patients with venous cerebral thrombosis, 338 with deep
venous thrombosis, 2 with portal vein thrombosis, and 31 other
venous thrombosis events. 
Factor V-Leiden and Prothrombin G20210A polymor-
phisms were tested by Real-time-PCR in the LightCycler
(Roche, Germany) using commercially available kits from the
same supplier. Previously, Factor V-Leiden and Prothrombin
G20210A had been tested by PCR-ASO using kits from
Vienna Labs (Austria). PCR-RFLP was also used in the past to
test for Factor-V-Leiden using a previously published protocol
(1). Methylenetetrahydrofolate Reductase (MTHFR) C677T
polymorphism was tested using previously described primers
and probes (2) with the DNA FastStart Hybridization probes
kit (Roche) optimised at 2.5 mM McCl2 and the following
thermal cycling protocol: Enzime activation at 94°C for 8 min-
utes followed by 40 round of amplification consisting on
denaturation at 94°C for 0 seconds, annealing at 55°C for 10
seconds and polymerisation at 72°C for 15 seconds.
Acquisition was performed during the annealing step.The
melting profile included an initial denaturation at 94°C for 0
seconds, a stabilization at 40°C for 5 seconds, and the melting
step with 80°C target temperature and stepwise acquisition at
0.6°C/second.
Serum levels of Protein C, Protein S and Antithrombin III
were assayed using the respective IL test on the ACL 9000 sys-
tem (Instrumentation Laboratory, USA), as recommended by
the manufacturer.
Comparison of polymorphism frequencies between groups
was done by the chi square test using the Statistica for
Windows software package (Statsoft).
Introduction and results
Thrombosis is a haematological disorder with variable
interacting causes that range from acquired to hereditary risk
factors (3-6). Over the last decade an increasing number of
genetic polymorphic markers associated with thrombosis have
been described – a  simple search on NCBI nucleotide data-
base (www.ncbi.nih.gov) with the words “thrombosis AND
Homo sapiens” returned at writing time 102 different entries,
corresponding to a total of 39 different genes. This list howev-
er does not include some genes with polymorphisms that rep-
resent weak risk factors for thrombosis such as the MTHFR
gene. In fact, a quick browse of the literature has allowed us to
generate a list of another 20 loci (3-7).  In addition to coagula-
tion risk factors, some immunological related polymorphic
loci may also mediate thrombosis risk, by modulating the pres-
ence of auto-antibodies that in turn modulate the plasma levels
of coagulation factors. Therefore, this already long list of
genetic risk factors for thrombosis should be regarded as a still
incomplete and evolving list.
Not only has this list of polymorphic loci modulating the
risk of thrombosis been growing, as the technical tools to study
them have been changing dramatically in the same period.
These improvements have enabled clinically useful genetic
testing for the diagnosis of diverse pathological situations such
as infectious, oncologic, and genetic diseases be them of a
monogenic or a multifactorial trait such as thrombosis.
The technical genotyping advances, although greatly
increasing speed, accuracy and volume, have also increased
the range of techniques used at any single moment in diverse
labs to test for the same parameter. This, in turn, has increased
the possibility that different laboratories testing the same sam-
ple would return divergent results. 
Genotyping experiments have evolved from the PCR-RFLP
techniques from late 1990’s to ARMS-PCR, PCR-ASO, and
more recently Real-Time-PCR with melting profile analysis.
Although the first techniques used are less expensive and eas-
ier to implement in a molecular biology lab, they are also more
prone to error, laborious, and far less convenient when a large
number of samples has to be studied. Despite these inconve-
nients, economical issues still make them a convenient choice
for many labs. 
One of PCR-RFLP’s most serious problems affecting result
fidelity is the occurrence of incomplete reactions, which
should be checked, using an internal universal restriction site.
However, this internal control is not always possible to imple-
ment, leaving some room for result uncertainty. 
ARMS-PCR is prone to false negative amplification reac-
tions caused by sample-to-sample variations in inhibitor con-
centrations. For this reason, an internal control is mandatory in
this procedure, and can only be substituted by the universal use
of an extra inhibition control reaction for each of the amplifi-
cation reactions. 
PCR-ASO is a useful and widely used technique due to the
possibility of automation in the microtiter plate based forms,
using the common and largely available ELISA automation
equipments. However, automation cannot by itself prevent
variations in PCR kinetics between different reactions (or
between different DNA templates in the same reaction). Since
genotyping usually relies on the comparison of end-point sig-
nal intensity, these variations can significantly influence the
results. In fact, in our lab, we have found that inter-reaction
variability can vary on average 13-26% (ranging from 0 to
173%). In order to control this variation we have implemented
as routine, the use of triplicates for any genotyping experiment
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by this method. As a result, from a total of 2840 reactions per-
formed in triplicate (a total of 8520 assays for wild-type
hybridisation probes and an equal amount with mutant
hybridisation probes), we found 275 reactions (9.7%) with at
least one discordant genotyping result. Of these, only 10
(0.4%) were completely discordant whereas the correct geno-
type of the remaining reactions could be deduced from the 2
concordant results. Nevertheless, if single reactions had been
performed, which is common practice in most labs for eco-
nomical reasons, up to 10% false results would be expected
from this procedure.
The advent of Real-Time-PCR, in its several probe flavours
(mainly molecular beacons, Taqman, Eclipse and FRET) has
allowed much faster amplification reactions (particularly with
the Smartcycler[Cepheid] and most notably with
LightCycler[Roche] technologies). Furthermore, because PCR
product detection is a part of the PCR reaction, the overall time
from PCR run to mutation detection can be greatly reduced (9-
11). Moreover, since PCR detection does not require PCR
product handling, nucleic acid contaminations attributable to
PCR products are virtually eliminated.
Regardless of these advantages, Real-Time-PCR amplifica-
tion also presents an additional feature, much valuable for
genotype analysis – the opportunity to perform melting curve
analysis, and therefore to determine the melting temperature of
a specific nucleic acid sequence (10-11). The melting point
determination is based on the fact that probe binding is a tem-
perature and sequence dependent process. Thus, temperature
ramping monitored by optical reading allows the machine to
detect a drop in signal that will occur when the probe specifi-
cally reaches its sequence-dependent melting temperature.
This variation in the fluorescence signal can be visualised by
plotting the negative derivate of the fluorescence intensity. In
this plot, a sudden decrease in signal strength is observed as a
peak (fig.1), making possible a clear discrimination between
homozygous wild-type, heterozygous and homozygous mutant
samples (fig.1).
Over the last 2 years, we moved from microplate PCR-ASO
hybridisation to a FRET based Real-Time-PCR procedure on
the LightCycler (Roche, Germany) for the genotyping of
Factor-V-Leiden, Prothrombin G20210A, and MTHFR C677T
polymorphisms.
A total of 863 individuals (226 normal controls, 253 arteri-
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Fig. 1. Negative derivative of the melting profile for Factor V
Leiden. Shown are the plots for homozygous wild-type (WT/WT),
heterozygous (WT/M) and homozygous mutant (M/M) samples.
Note that the observed peaks for the two alleles are well separated,
making genotype discrimination simple and unambiguous.
Table 1. Frequency of Wild-Type and mutated alleles in patients and controls
Significance value
Genotype/phenotype a) Alleleb) Controls ATcb) VT c) AT/VTc) C/AT c) C/VT c)
Factor V-Leiden WT 221 242 327 <0.00001 n.s. <0.00001
M 5 6 53
PTH WT 214 237 347 <0.0236 n.s. n.s.
M 12 9 31
MTHFR WT 95 111 142 n.s. n.s. n.s.
M 119 132 228
ATIII N 30 221 316 n.s. n.s. n.s.
Low 0 1 7
Prot. C N 30 211 293 <0.0046 n.s. n.s.
Low 0 5 26
Prot. S N 30 202 289 n.s. n.s. n.s.
Low 0 12 30
a) Factor V leiden, Prothrombin and MTHFR refer to the respective genotypes, whereas ATIII, Prot.C and Proc.S refer to the relative protein levels
and are therefore phenotype determinations. All data available for each genotypic marker was included.
b) WT=Wild-type; M=mutated
c) AT=Arterial Thrombosis; VT=Venous thrombosis; C=control
al thrombosis patients [AT] and 384 venous thrombosis
patients [VT]) were studied by genotyping procedures. In a
subgroup of 547 individuals (40 normal controls, 204 AT and
303 VT patients) serum levels of Protein C, Protein S and
Antithrombin III were also studied. As can be seen in table 1
the frequency of genetic polymorphisms/mutations found in
the 863 individuals tested confirms that Factor V-Leiden is
individually the genetic marker with the highest value in the
discrimination of thrombotic genetic risk among venous
thrombosis patients. Two other markers were found to be sig-
nificantly different among venous and arterial thrombosis
patients (Prothrombin G20210A, and reduced levels of protein
C). In both cases, abnormalities were more frequent among
venous thrombosis patients than among arterial thrombosis
patients. In addition, none of the studied markers was found to
individually show correlation to arterial thrombosis.
Although there is no significant correlation between most
of the studied parameters alone and thrombosis, we were able
to find an association between combined factors and increased
thrombosis risk.
As can be seen in table 2, indeed when taken together, the
studied risk factors are found to better discriminate between
patients and controls, and between patient groups than when
used alone. Interestingly, even modest thrombosis risk factors
such as MTHFR C677T polymorphisms were found to con-
tribute significantly to the global risk factor in the patient
group. In fact, when the MTHFR polymorphism is only
included in the last step (table 3), the increase in the number of
patients identified by the inclusion of each additional factor is
very small when compared to the observed when MTHFR is
included (13 versus 78 in VT and 4 versus 34 in AT).
Therefore, our results show that even common polymorphisms
cannot be excluded from investigation as they can be found to
contribute significantly to the clarification of the global throm-
bosis genetic risk factor in any individual patient.
Discussion
The growing list of polymorphic loci relevantly influencing
the genetic risk of thrombosis raises the discussion to the point
of discriminating the most relevant loci for the study (4,7).
This is due to the economical and technical burden of studying
an elevated number of genetic polymorphisms, each with a
small contribution to the global risk. In this regard, it must be
stressed that although this approach seems wise under the
present technological tools available in the clinical laboratory,
it is an ever-changing situation as recent history is showing. 
From the techniques already available to the routine clini-
cal laboratory, Real-Time-PCR with melting profile analysis
seems to be the one that presents the best characteristics in
terms of cost, reproducibility, speed, sensitivity and specifici-
ty. Its level of automation, and the absence of PCR products
handling greatly reduce the human expertise and the laborato-
ry constrains necessary to its implementation. Also, the speed
at which each reaction can be performed allows a much high-
er number of reactions per patient to be performed on the same
day, thus increasing the feasibility of multi-locus typing. This
can be even easier when machines such as the SmartCycler
series (Cepheid, USA) are used, as they allow the simultane-
ous run of different protocols for the same sample in separate
reaction vessels. 
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Table 2. Frequency of associated polymorphic risk markers of thrombosis
Significance level
Genotype/phenotype a) # risk markers b) C c) AT c) VT c) AT/VT c)
Factor V-Leiden ≤1 40 204 303
>1 0 0 0
+ PTH ≤1 40 203 300 n.s.
>1 0 1 3
+ MTHFR ≤1 33 174 233 <0.0198
>1 7 30 70
+ ATIII ≤1 33 173 230 <0.0150
>1 7 31 73
+ Prot. C ≤1 33 171 222 <0.0052
>1 7 33 81
+ Prot. S ≤1 33 166 208 <0.0014
>1 7 38 95
a) Factor V leiden, Prothrombin and MTHFR refer to the respective genotypes, whereas ATIII, Prot.C and Proc.S refer to the relative protein levels
and are therefore phenotype determinations. Only data of individuals with all genotyping/phenotypic markers tested were included
b) Number of risk markers refers to the total number of risk markers found in each patient when considering only the genotypes/phenotypes from top
of the table to each line. Note that for genotype markers each allele was considered one marker, thus an homozygous mutant individual would be con-
sidered to have 2 risk markers.
c) AT=Arterial Thrombosis; VT=Venous thrombosis; C=control
Thus, at present, with the availability of Real-Time-PCR
with melting profile analysis, the study should in our opinion
include, not only the very strong risk factors such as Factor V-
Leiden, but also some weaker factors, and common polymor-
phisms such as Prothrombin G20210A and MTHFR C677T at
a minimum. The conjugated study of these factors, not only
allows the clarification of the genetic risk of more patients, as
allows a clearer stratification of the genetic risk, due to associ-
ation of several risk factors (12-13). Another complementary
approach may be to study, at the protein level, some other
genetic risk factors such as Proteins C and S, Antithrombin III
and PAI-1, as these are more difficult to study at the genetic
level (due to the nature or number of mutations to be screened).
The results here described do indeed suggest that the con-
jugation of these strategies allows a clearer elucidation of the
genetic risk of each patient, and also a clearer stratification of
the genetic risk differences between patients, with potential
clinical benefits in terms of differential patient management. 
Real-Time-PCR is so far the best of the genotyping tech-
niques available in the clinical molecular biology laboratory.
However, this is about to change in the near future, as prob-
lems with the miniaturized devices being developed over the
last decade are solved, and these devices approach the com-
mercial status, with costs reaching affordable values.
Miniaturized devices are being developed for nucleic acid
extraction, capillary electrophoresis, PCR, multiplex-PCR,
degenerate oligonucleotide primed PCR, Ligase chain reac-
tion, RFLP and hybridisation assays, as well as combinations
of these (14-16). Many of these devices are still in an early
development stage, and for this reason can only be used in the
research setting (16). However, some of these devices have
already matured enough to be released commercially, such as
the Lab-on-a-chip (Agilent) for capillary electrophoresis and
multiple examples of hybridisation chips. For the most part,
the major obstacle to the use of these devices in current diag-
nostic procedures is cost, and this is expected to drop signifi-
cantly as their use increases, and production and development
costs dilute with quantity. Also, as these devices become more
widely used, the lab and personel constraints characteristic of
any clinical molecular biology lab nowadays are expected to
diminish, making these techniques available in most clinical
laboratories. Also, as specific devices for disease risk factor
genotyping become available, the number of tested risk-factors
per patient is also expected to climb (current commercial ver-
sions of DNA chips hold up to 20,000-45,000 probes in a 1.28
cm2 area [16]), making conclusions on a patient basis clearer,
as more of the combined risk factors get tested.
In conclusion, as a fast evolving discipline, clinical molecu-
lar genetics is quickly changing, both at the laboratory desk and
at the clinical setting. In these changing times, care must be
taken to ensure not only adequate testing, but also correct clin-
ical interpretation of the available, but incomplete data.
However, as miniaturization proceeds, it is expected that both
completeness of the data, as well as reproducibility and stan-
dardization at the lab desk results in data easier to obtain and to
interpret.
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Table 3. Frequency of associated polymorphic risk markers of thrombosis
# individuals Significance level
Genotype/phenotype a) # risk markers b) C c) AT c) VT c) AT/VT c)
Factor V-Leiden ≤1 40 204 303 n.s.
>1 0 0 0
+ PTH ≤1 40 203 300 n.s.
>1 0 1 3
+ ATIII ≤1 40 203 300 n.s.
>1 0 1 3
+ Prot. C ≤1 40 202 295 n.s.
>1 0 2 8
+ Prot. S ≤1 40 200 289 n.s.
>1 0 4 14
+ MTHFR ≤1 33 166 208 0.0014
>1 7 38 95
a) Factor V leiden, Prothrombin and MTHFR refer to the respective genotypes, whereas ATIII, Prot.C and Proc.S refer to the relative protein levels
and are therefore phenotype determinations. Only data of individuals with all genotyping/phenotypic markers tested were included
b) Number of risk markers refers to the total number of risk markers found in each patient when considering only the genotypes/phenotypes from top
of the table to each line. Note that for genotype markers each allele was considered one marker, thus an homozygous mutant individual would be con-
sidered to have 2 risk markers.
c) AT=Arterial Thrombosis; VT=Venous thrombosis; C=control
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